Estrogen and progesterone receptor expression in HPV-positive and HPV-negative cervical carcinomas

Oncology Reports

Volumn 26, Issue 1, 2011, Pages 153-160

  Kwasniewska, Anna ^a   Postawski, Krzysztof ^a   Gozdzicka Jozefiak, Anna ^b   Kwasniewski, Wojciech ^a   Grywalska, Ewelina ^a   Zdunek, Malgorzata ^a   Korobowicz, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Cervical cancer; Estrogen receptor; Human papillomavirus; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; VIRUS DNA;

ADENOCARCINOMA; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYOMECTOMY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA CELL; UTERINE CERVIX CARCINOMA; WART VIRUS;

ADENOCARCINOMA; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; CERVIX UTERI; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; UTERINE CERVICAL NEOPLASMS;

EID: 79955865099     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1256     Document Type: Article

References (45)

1. Zur Hausen H: Oncogenic DNA viruses. Oncogene 20: 7820-7823, 2001.
2. Smith JS, Lindsay L, Hoots B, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632, 2007. (Pubitemid 46986496)
3. Mitrani-Rosenbaum S, Tsvieli R and Tur-Kaspa R: Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 70: 2227-2232, 1989. (Pubitemid 19215129)
4. Altekruse SF, Lacey JV Jr, Brinton LA, et al: Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol 188: 657-663, 2003. (Pubitemid 36332430)
5. Jayshree RS, Sreenivas A, Tessy M and Krishna S: Cell intrinsic and extrinsic factors in cervical carcinogenesis. Indian J Med Res 130: 286-295, 2009.
6. Chan WK, Klock G and Bernard HU: Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 63: 3261-3269, 1989. (Pubitemid 19181382)
7. Pittayakhajonwut D and Angeletti PC: Viral trans-factor independent replication of human papillomavirus genomes. Virol J 7: 123, 2010.
8. Bromberg-White JL and Meyers C: The upstream regulatory region of human papillomavirus type 31 is insensitive to glucocorticoid induction. J Virol 76: 9702-9715, 2002. (Pubitemid 35006511)
9. Chen YH, Huang LH and Chen TM: Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 224: 651-659, 1996.
10. Kedzia W, Gozdzicka-Jozefiak A, Kwasniewska A, Schmidt M, Miturski R and Spaczynski M: Relationship between HPV infection of the cervix and blood serum levels of steroid hormones among pre- and postmenopausal women. Eur J Gynaecol Oncol 21: 177-179, 2000. (Pubitemid 30240605)
11. Kim CJ, Um SJ, Kim TY, et al: Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer 10: 157-164, 2000. (Pubitemid 30351316)
12. Cogliano V: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomavirus. International Agency for Research on Cancer. Lyon, 2007.
13. Auborn KJ, Woodworth C, DiPaolo JA and Bradlow HL: The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer 49: 867-869, 1991.
14. Remoue F, Jacobs N and Miot V: High intraepithelial expression of estrogen and progesterone receptors in the transformation zone of the uterine cervix. Am J Obstet Gynecol 189: 1660-1655, 2003.
15. Madeleine MM, Daling JR, Schwartz SM, et al: Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 10: 171-177, 2001. (Pubitemid 34288526)
16. Moreno V, Bosch FX, Munoz N, et al: Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359: 1085-1092, 2002. (Pubitemid 34270731)
17. Smith JS, Green J, Berrington de Gonzalez A, et al: Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361: 1159-1167, 2003. (Pubitemid 36401593)
18. Salazar EL, Sojo-Aranda I, López R and Salcedo M: The evidence for an etiological relationship between oral contraceptive use and dysplastic change in cervical tissue. Gynecol Endocrinol 15: 23-28, 2001. (Pubitemid 32234884)
19. Arbeit JM, Howley PM and Hanahan D: Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 93: 2930-2935, 1996. (Pubitemid 26114341)
20. Chung SH, Wiedmeyer K and Shai A: Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res 68: 9928-9934, 2008.
21. Mosselman S, Polman J and Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996. (Pubitemid 26268330)
22. Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R and Strissel PL: Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci 66: 2405-2426, 2009.
23. Nilsson S, Mäkelä S, Treuter E, et al: Mechanisms of estrogen action. Physiol Rev 81: 1535-1565, 2001.
24. Cavaillès V: Estrogens and receptors: an evolving concept. Climacteric 5 (Suppl. 2): S20-S26, 2002.
25. Lazari MF, Lucas TF, Yasuhara F, et al: Estrogen receptors and function in the male reproductive system. Arq Bras Endocrinol Metabol 53: 923-933, 2009.
26. Scarpin KM, Graham JD, Mote PA and Clarke CL: Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal 7: e009, 2009.
27. Tavassoéli FA and Devilee P: World Health Organization Classification of Tumors: Pathology and Genetics. Tumors of the Breast and Female Genital Organs. IARC Press, Lyon, 2003.
28. Benedet JL, Bender H, Jones H III, Ngan HY and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70: 209-262, 2000.
29. Bloch B: Hormone receptors in cervical intraepithelial neoplasia. Obstet Gynecol Surv 34: 868-869, 1979.
30. Monsonego J, Magdelenat H, Catalan F, Coscas Y, Zerat L and Sastre X: Estrogen and progesterone receptors in cervical human papillomavirus-related lesions. Int J Cancer 48: 533-539, 1991.
31. Kim JW, Sung HR, Kim DK and Song CH: Estrogen and progesterone receptor assay in carcinoma of the cervix with monoclonal antibodies. Gynecol Oncol 47: 306-310, 1992.
32. Masood S, Rhatigan RM, Wilkinson EW, Barwick KW and Wilson WJ: Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. Cancer 72: 511-518, 1993. (Pubitemid 23193460)
33. González Sánchez JL, Chávez Brambila J, Maricela Román A, Infante Martínez R and Salazar Esquivel LE: Value of estrogen and progesterone receptors in the management of intraepithelial squamous lesions of low grade. Ginecol Obstet Mex 69: 1-5, 2001.
34. Moodley J: Combined oral contraceptives and cervical cancer. Curr Opin Obstet Gynecol 16: 27-29, 2004.
35. Bekkers RL, van der Avoort IA, Melchers WJ, Bulten J, de Wilde PC and Massuger LF: Down regulation of estrogen receptor expression is an early event in human papillomavirus infected cervical dysplasia. Eur J Gynaecol Oncol 26: 376-382, 2005. (Pubitemid 41139462)
36. Fonseca-Moutinho JA, Cruz E, Carvalho L, et al: Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III. Int J Gynecol Cancer 14: 911-920, 2004. (Pubitemid 39238179)
37. Potish RA, Twiggs LB, Adcock LL, Prem KA, Savage JE and Leung BS: Prognostic importance of progesterone and estrogen receptors in cancer of the uterine cervix. Cancer 58: 1709-1713, 1986. (Pubitemid 16032154)
38. Hunter RE, Longcope C and Keough P: Steroid hormone receptors in carcinoma of the cervix. Cancer 60: 392-396, 1987. (Pubitemid 17098606)
39. Nonogaki H, Fujii S, Konishi I, Nanbu Y, Ozaki S, Ishikawa Y and Mori T: Estrogen receptor localization in normal and neoplastic epithelium of the uterine cervix. Cancer 66: 2620-2627; 1990.
40. Coelho FR, Prado JC, Pereira Sobrinho JS, et al: Estrogen and progesterone receptors in human papilloma virus-related cervical neoplasia. Braz J Med Biol Res 37: 83-88, 2004. (Pubitemid 38240148)
41. Teyssier C, Belguise K, Galtier F and Chalbos D: Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. J Biol Chem 276: 36361-36369, 2001.
42. Levy N, Tatomer D, Herber CB, et al: Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol 22: 287-303, 2008. (Pubitemid 351185932)
43. Saville B, Wormke M, Wang F, et al: Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379-5387, 2000. (Pubitemid 30115168)
44. Safe S and Kim K: Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41: 263-275, 2008.
45. Rae JM and Johnson MD: What does an orphan G-protein-coupled receptor have to do with estrogen? Breast Cancer Res 7: 243-244, 2005.